DOCSLIB.ORG

A Crossover Comparison of Extended Release Felodipine with Prolonged Action Nifedipine in Arch Dis Child: First Published As 10.1136/Adc.73.2.154 on 1 August 1995

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Crossover Comparison of Extended Release Felodipine with Prolonged Action Nifedipine in Arch Dis Child: First Published As 10.1136/Adc.73.2.154 on 1 August 1995 154 Archives ofDisease in Childhood 1995; 73: 154-156 A crossover comparison of extended release felodipine with prolonged action nifedipine in Arch Dis Child: first published as 10.1136/adc.73.2.154 on 1 August 1995. Downloaded from hypertension Ileana Moncica, Paul I Oh, Izhar ul Qamar, Dennis Scolnik, Gerald S Arbus, Diane Hebert, J Williamson Balfe, Gideon Koren Abstract felodipine, was introduced in 1991 and has In a crossover design, control of blood also been found to be effective in adults.5 6 pressure by extended release felodipine This drug is available as an extended release was compared with control by prolonged (ER) formulation which has the advantage of action nifedipine in 21 children with renal once daily administration and potentially hypertension. Compliance with once daily improved compliance. felodipine was higher than with nifedipine, The issue of compliance with chronic medi- at 95-6 (SEM 2.7)% v 78 9 (60)% (p=0-02). cations in children is a serious problem, and Mean diastolic blood pressure was lower attempts to decrease the frequency of drug during the day with felodipine than with dosage are a potential way of improving nifedipine, at 77*6 (2.4) v 84-4 (2-8) mm Hg compliance.7 The objective of our study was to (p=O05). Similarly, blood pressure load evaluate the effectiveness of felodipine-ER (the percentage of the day during which (Plendil, Astra Pharma) by comparing it with the child had blood pressure exceeding nifedipine-PA (Adalat, Miles) in the treatment the upper limits of normal for age) was of children with hypertension predominantly lower for felodipine than for nifedipine: due to renal disease, in a randomised crossover 43-5 (5.5)% v 61'3 (6.3)%. There was an design. We also assessed improvement in opposite trend during the night, though patients' compliance during use of once daily this did not reach statistical significance. felodipine-ER. To the best of our knowledge These data suggest that once a day this is the first paediatric study with this felodipine is effective in children with agent. hypertension. This may be because of improved compliance. (Arch Dis Child 1995; 73: 154-156) Methods PATIENTS Keywords: hypertension, felodipine, nifedipine. Twenty one hypertensive children between the http://adc.bmj.com/ ages of 6 and 18 years who had been receiving nifedipine-PA treatment were asked to partici- Hypertension occurs in 1-3% of the paediatric pate in the study. Most of these patients population.' In distinction to adults, most of (18/21) had undergone renal transplantation. the children under the age of 12 years have a Before initiating this protocol, home and clinic secondary form of hypertension, most com- blood pressure had been followed closely and monly due to renal parenchymal or renovascu- exceeded the 95th centile for normal subjects on September 24, 2021 by guest. Protected copyright. lar disease, coarctation of the aorta, or of matched age and gender for at least four out endocrine abnormalities.' The more severe of seven days of the week with two measure- The Hospital for Sick Children, Toronto, forms ofhypertension are seen in children with ments per day. Patients were excluded if their Canada renal disease either before or after renal trans- control or treatment of hypertension had been plantation. unstable during the preceding month or if they Division of Clinical Pharmacology/ Development of antihypertensive medica- were unable to swallow the 9 mm diameter Toxicology tions in paediatric patients has lagged behind felodipine tablet. I Moncica treatment in adults. Because of concerns about The study protocol was approved by our P I Oh new have research ethics committee. I ul Qamar safety and efficacy, trials of agents hospital's D Scolnik almost universally excluded children. Traditionally treatment therefore has been Division ofNephrology diuretics.2 Calcium PROCEDURES G S Arbus limited to e blockers and D Hebert channel blockers have been widely and effec- Eligible patients were randomised by a random J W Balfe tively used in adults but have only recently number table to receive treatment with been introduced to patients. The felodipine-ER or nifedipine-PA for one month Department of paediatric Pediatrics dihydropyridine calcium channel blockers are and then crossed over to the other agent. G Koren particularly potent smooth muscle relaxants Patients and parents were not blinded to the and may therefore be study drugs because of the different appear- Correspondence to: and arterial vasodilators, Gideon Koren MD, especially useful in patients with hypertension. ance and dosage schedules, but the physicians Division of Clinical were unaware of the Pharmacology/Toxicology, Nifedipine prolonged action (PA), which is in the clinic assigned The Hospital for Sick given two or three times a day, often in combi- drugs for the duration of the study. The start- Children, 555 University was set at one of Avenue, Toronto, Ontario, nation with other drugs, has played an import- ing dose of felodipine quarter Canada M5G 1X8 ant part in the treatment of such patients.3 4 the nifedipine daily dose5 6 up to a maximum Accepted 24 April 1995 A new dihydropyridine calcium antagonist, of 20 mg per day. Dose adjustments were Felodipine versus nifedipine in hypertension 155 Table 1 Comparison of blood pressure control: nifedipine twice daily vfelodipine once STATISTICAL CONSIDERATIONS AND ANALYSES daily. Values are means (SEM) The primary endpoint of the study was a Arch Dis Child: first published as 10.1136/adc.73.2.154 on 1 August 1995. Downloaded from Nifedipine Felodipine paired comparison of the mean daytime therapy therapy Significance average ambulatory blood pressure at steady Compared value (SEM) (SEM) Differences (p) state with felodipine-ER versus nifedipine-PA. ABP - systolic day (mm Hg) 134 (3 6) 128-5 (3-6) 7-1 (2 6) NS We anticipated that the daytime diastolic ABP - diastolic day (mm Hg) 84-4 (2 8) 77-6 (2 4) 0-05 in ABP- systolic night (mm Hg) 123 (3-9) 125-1 (3-4) NS blood pressure might be lower the felodipine ABP - diastolic night (mm Hg) 75-5 (3) 81-1 (2-7) NS phase due to a smoother and longer duration % High systolic day 58-2 (6-4) 49 7 (6 5) NS % High diastolic day 61-3 (6-3) 43-5 (5 5) 18 (5 9) 0 03 of action compared with nifedipine-PA. A % High systolic night 31-3 (7) 44-3 (8 2) 13 (7 5) 0 04 sample size of 20 patients was needed for a % High diastolic night 44 9 (8-9) 53-5 (8-3) NS a or Home - systolic day (mm Hg) 125-8 (2-5) 123 (2 8) 2-8 (2 6) 0 05 median effect size (half SD around 8 mm Home -diastolic day (mmHg) 77-8 (1-6) 76-2 (1 9) 1-6 (1-7) 0-02 Hg) difference in blood pressure between the two drugs to be significant with ot of 0 05 and ABP=ambulatory blood pressure measured continuously for 24 hours; Home=blood pressure measured manually at home by parents/patients; % High=percentage of time with blood power of 80%. Secondary endpoints were pressure at values greater than mean +2 SD for age. nocturnal blood pressure control assessed on home and ABP, proportions of blood pressure readings on ABP above the 95th percentile for made individually depending on blood pres- age, and assessments of compliance. The sure response and monitoring of adverse paired t test was used for comparisons between effects by an independent physician. the two arms of the study. Data are presented as mean (SEM). BLOOD PRESSURE MEASUREMENTS During the study, patients or parents Results measured blood pressure in the arm at home Both drugs were well tolerated by all partici- three times per day, using an automated pants and there were no dropouts. Children device, and recorded the values in a diary. received a mean nifedipine dose of 58-9 (5-1) The cuff size was two thirds of the arm length, mg/d and felodipine at 13 4 (1 1) mg/d. There and all measurements were performed with were no differences in the doses of concomi- the child in the sitting position. Blood tant drugs (other antihypertensives, pred- pressure at each clinic visit was measured in nisone, cyclosporin) given during the two arms triplicate manually with a mercury sphygmo- of the study, and serum creatinine did not manometer and with an automated Dinamap differ between the two phases. recorder (Critikon). Ambulatory blood During the day, diastolic blood pressure pressure (ABP) was recorded over a 24 hour with felodipine was significantly lower than period using a Takeda blood pressure with nifedipine (table 1). A similar trend with monitor model TM 2420 (A and D systolic blood pressure was not statistically Engineering) at the end of each month of significant. During the night the trends drug treatment. ABP was analysed separately reversed, with nifedipine tending to be http://adc.bmj.com/ for daytime (8 am to 10 pm) and night time associated with lower blood pressure; (10 pm to 8 am). however, the trend did not reach statistical significance. Similar effects were documented with the percentage of time the blood COMPLIANCE pressure was above the 95% percentile for age Compliance was assessed by the Medication (table 1). Event Monitoring System (MEMS, Aprex), a Compliance (that is, percentage of drug on September 24, 2021 by guest. Protected copyright. computerised tracking device in which an elec- taken v prescribed) was significantly higher tronic chip in the lid of the container records with felodipine (table 2). Compliance with the the date and time that the bottle is opened. evening dose of nifedipine tended to be better The parents and children were not aware ofthe than with the morning dose, at 84-7 (7.7)% v electronic monitoring device.
Load more

Recommended publications
  • Investigating the Influence of Polymers on Supersaturated
    Page 1 of 45 Molecular Pharmaceutics 1 2 3 4 5 6 7 Investigating the Influence of Polymers on 8 9 10 11 12 Supersaturated Flufenamic Acid Cocrystal Solutions 13 14 15 16 1 1 2 2 1 17 Minshan Guo , Ke Wang , Noel Hamill , Keith Lorimer and Mingzhong Li * 18 19 20 1School of pharmacy, De Montfort University, Leicester, UK 21 22 23 2Almac Science, Seagoe Industrial Estate, Craigavon, UK 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 ACS Paragon Plus Environment 1 Molecular Pharmaceutics Page 2 of 45 1 2 3 4 5 6 7 Table of contents graphic 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 ACS Paragon Plus Environment 2 Page 3 of 45 Molecular Pharmaceutics 1 2 3 Abstract 4 5 6 7 The development of enabling formulations is a key stage when demonstrating the effectiveness 8 9 10 of pharmaceutical cocrystals to maximize the oral bioavailability for poorly water soluble drugs. 11 12 Inhibition of drug crystallization from a supersaturated cocrystal solution through a fundamental 13 14 understanding of the nucleation and crystal growth is important. In this study, the influence of 15 16 17 the three polymers of polyethylene glycol (PEG), polyvinylpyrrolidone (PVP) and a copolymer 18 19 of N-vinly-2-pyrrodidone (60%) and vinyl acetate (40%) (PVP-VA) on the flufenamic acid 20 21 22 (FFA) crystallization from three different supersaturated solutions of the pure FFA and two 23 24 cocrystals of FFA-NIC CO and FFA-TP CO has been investigated by measuring nucleation 25 26 induction times and desupersaturation rates in the presence and absence of seed crystals.
    [Show full text]
  • Optum Essential Health Benefits Enhanced Formulary PDL January
    PENICILLINS ketorolac tromethamineQL GENERIC mefenamic acid amoxicillin/clavulanate potassium nabumetone amoxicillin/clavulanate potassium ER naproxen January 2016 ampicillin naproxen sodium ampicillin sodium naproxen sodium CR ESSENTIAL HEALTH BENEFITS ampicillin-sulbactam naproxen sodium ER ENHANCED PREFERRED DRUG LIST nafcillin sodium naproxen DR The Optum Preferred Drug List is a guide identifying oxacillin sodium oxaprozin preferred brand-name medicines within select penicillin G potassium piroxicam therapeutic categories. The Preferred Drug List may piperacillin sodium/ tazobactam sulindac not include all drugs covered by your prescription sodium tolmetin sodium drug benefit. Generic medicines are available within many of the therapeutic categories listed, in addition piperacillin sodium/tazobactam Fenoprofen Calcium sodium to categories not listed, and should be considered Meclofenamate Sodium piperacillin/tazobactam as the first line of prescribing. Tolmetin Sodium Amoxicillin/Clavulanate Potassium LOW COST GENERIC PREFERRED For benefit coverage or restrictions please check indomethacin your benefit plan document(s). This listing is revised Augmentin meloxicam periodically as new drugs and new prescribing LOW COST GENERIC naproxen kit information becomes available. It is recommended amoxicillin that you bring this list of medications when you or a dicloxacillin sodium CARDIOVASCULAR covered family member sees a physician or other penicillin v potassium ACE-INHIBITORS healthcare provider. GENERIC QUINOLONES captopril ANTI-INFECTIVES
    [Show full text]
  • Effect of Felodipine Against Pilocarpine Induced Seizures in Rats
    Int. J. Pharm. Sci. Rev. Res., 52(1), September - October 2018; Article No. 10, Pages: 54-60 ISSN 0976 – 044X Research Article Effect of Felodipine against Pilocarpine induced Seizures in Rats Osama Q. Fadheel 1, Faruk H. AL-Jawad 1, Waleed K. Abdulsahib 2, Haider F. Ghazi 3 1Pharmacology Department, College of Medicine, Al-Nahrain University, Baghdad, Iraq. 2Pharmacy department, Al- Farahidi University College, Baghdad, Iraq. 3Microbiology Department, College of Medicine, Al-Nahrain University, Iraq. *Corresponding author’s E-mail: [email protected] Received: 25-07-2018; Revised: 22-08-2018; Accepted: 05-09-2018. ABSTRACT Epilepsy is a standout amongst the most well-known genuine cerebrum issue, can happen at all ages. The examination was performed to investigate the conceivable antiepileptic impact of Felodipine against pilocarpine prompted seizure in male rats. The investigation did on forty male Wister rats similarly assigned to four gathering: (1) typical gathering (not got any medication). Gathering (2) negative control gathering (got just pilocarpine amid acceptance of seizure. Gathering (3) positive control gathering (Valproic corrosive gathering got 20 mg/kg orally twice every day). Gathering (4) Felodipine gathering (1 mg/kg got orally once every day). Rats of each gathering (aside from typical gathering) were infused intraperitoneal with pilocarpine hydrochloride (400 mg/kg) following 21 long stretches of tried medications organization orally. The mean beginning and term of seizure were resolved to assess the viability of tried medications and to contrast these impact and that of typical gathering and Valproic corrosive gathering. Additionally, neuroprotective impact (Neu N), NMDA receptor, Sodium diverts were estimated in all gatherings.
    [Show full text]
  • Association of Hypertensive Status and Its Drug Treatment with Lipid and Haemostatic Factors in Middle-Aged Men: the PRIME Study
    Journal of Human Hypertension (2000) 14, 511–518 2000 Macmillan Publishers Ltd All rights reserved 0950-9240/00 $15.00 www.nature.com/jhh ORIGINAL ARTICLE Association of hypertensive status and its drug treatment with lipid and haemostatic factors in middle-aged men: the PRIME Study P Marques-Vidal1, M Montaye2, B Haas3, A Bingham4, A Evans5, I Juhan-Vague6, J Ferrie`res1, G Luc2, P Amouyel2, D Arveiler3, D McMaster5, JB Ruidavets1, J-M Bard2, PY Scarabin4 and P Ducimetie`re4 1INSERM U518, Faculte´ de Me´decine Purpan, Toulouse, France; 2MONICA-Lille, Institut Pasteur de Lille, Lille, France; 3MONICA-Strasbourg, Laboratoire d’Epide´miologie et de Sante´ Publique, Strasbourg, France; 4INSERM U258, Hoˆ pital Broussais, Paris, France; 5Belfast-MONICA, Department of Epidemiology, The Queen’s University of Belfast, UK; 6Laboratory of Haematology, La Timone Hospital, Marseille, France Aims: To assess the association of hypertensive status this effect remained after multivariate adjustment. Cal- and antihypertensive drug treatment with lipid and hae- cium channel blockers decreased total cholesterol and mostatic levels in middle-aged men. apoproteins A-I and B; those differences remained sig- Methods and results: Hypertensive status, antihyperten- nificant after multivariate adjustment. ACE inhibitors sive drug treatment, total and high-density lipoprotein decreased total cholesterol, triglycerides, apoprotein B (HDL) cholesterol, triglyceride, apoproteins A-I and B, and LpE:B; and this effect remained after multivariate lipoparticles LpA-I,
    [Show full text]
  • Dorset Medicines Advisory Group
    DORSET CARDIOLOGY WORKING GROUP GUIDELINE FOR CALCIUM CHANNEL BLOCKERS IN HYPERTENSION SUMMARY The pan-Dorset cardiology working group continues to recommend the use of amlodipine (a third generation dihydropyridine calcium-channel blocker) as first choice calcium channel blocker on the pan-Dorset formulary for hypertension. Lercanidipine is second choice, lacidipine third choice and felodipine is fourth choice. This is due to preferable side effect profiles in terms of ankle oedema and relative costs of the preparations. Note: where angina is the primary indication or is a co-morbidity prescribers must check against the specific product characteristics (SPC) for an individual drug to confirm this is a licensed indication. N.B. Lacidipine and lercandipine are only licensed for use in hypertension. Chapter 02.06.02 CCBs section of the Formulary has undergone an evidence-based review. A comprehensive literature search was carried out on NHS Evidence, Medline, EMBASE, Cochrane Database, and UK Duets. This was for recent reviews or meta-analyses on calcium channel blockers from 2009 onwards (comparative efficacy and side effects) and randomised controlled trials (RCTs). REVIEW BACKGROUND Very little good quality evidence exists. No reviews, meta-analyses or RCTs were found covering all calcium channel blockers currently on the formulary. Another limitation was difficulty obtaining full text original papers for some of the references therefore having to use those from more obscure journals instead. Some discrepancies exist between classification of generations of dihydropyridine CCBs, depending upon the year of publication of the reference/authors’ interpretation. Dihydropyridine (DHP) CCBs tend to be more potent vasodilators than non-dihydropyridine (non-DHP) CCBs (diltiazem, verapamil), but the latter have greater inotropic effects.
    [Show full text]
  • Evaluation of Therapeutic Drug Monitoring (TDM) on Older Antiepileptic Medications
    Available online a t www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 2015, 7 (2):243-250 (http://scholarsresearchlibrary.com/archive.html) ISSN 0975-5071 USA CODEN: DPLEB4 Evaluation of therapeutic drug monitoring (TDM) on older antiepileptic medications Dayana Nicholas* 1, Azmi Bin Sarriff 2, Tharmalingam Palanivelu 3, Kenneth Nelson 4 and Samson P. George 5 1Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, AIMST University, Bedong, Kedah, Malaysia 2School of Pharmaceutical Sciences, Department of Clinical Pharmacy & Faculty of Pharmacy, University Sains Malaysia, Penang, Malaysia 3Consultant Physician and Head of Department, Department of Medicine, Hospital Sultan Abdhul Halim, Malaysia 4Department of Pharmacy Practice, Faculty of Pharmacy, Grace College of Pharmacy, Kerala, India 5Drug Information Centre, Karnataka State Pharmacy Council, Bangalore, Karnataka, India _____________________________________________________________________________________________ ABSTRACT The Prospective study was conducted to evaluate the measure of Therapeutic Drug Monitoring (TDM) services on conventional antiepileptic drugs (AEDs) in 160 epileptic patients’ data of children and adults with both genders was on AEDs. The study results have shown 66 patients (50.38%), under subtherapeutic range on single AEDs with phenytoin and Na.valproate. In 160 patients, 13 of 98 (13.54%) adult patients received co-medication and 3 of 62 (6.25%) children with co-medications. Overall average (Vd) for carbamazepine in adult and children patients was found to be 78.25L which was higher than Vd for phenytoin (35.12L) and Na.Valproate (11.73L). The overall mean of clearance (Cl) for phenytoin (35.59L/hr) was found to be the highest, followed by Carbamazepine (3.81L/hr) and Na.Valproate (0.40L/hr).
    [Show full text]
  • Package Insert Template for Felodipine Extended Release Tablet
    PACKAGE INSERT TEMPLATE FOR FELODIPINE EXTENDED RELEASE TABLET Brand or Product Name [Product name] ER Tablet 2.5mg [Product name] ER Tablet 5mg [Product name] ER Tablet 10mg Name and Strength of Active Substance(s) Felodipine 2.5mg Felodipine 5mg Felodipine 10mg Product Description [Visual description of the appearance of the product (eg colour, markings etc) eg White, circular flat beveled edge extended release tablets marked ‘10’ on one side] Pharmacodynamics Felodipine is a vascular selective calcium antagonist which lowers arterial blood pressure by decreasing systemic vascular resistance. Due to the high degree of selectivity for smooth muscle in the arterioles, felodipine in therapeutic doses has no direct effect on cardiac contractility or conduction. Because there is no effect on venous smooth muscle or adrenergic vasomotor control, felodipine is not associated with orthostatic hypotension. Felodipine possesses a mild natriuretic/diuretic effect and fluid retention does not occur. Felodipine is effective in all grades of hypertension. It can be used as monotherapy or in combination with other antihypertensive drugs, e.g. ß-adrenoceptor blockers, diuretics or ACE-inhibitors, in order to achieve an increased antihypertensive effect. Felodipine reduces both systolic and diastolic blood pressure and can be used in isolated systolic hypertension. Felodipine maintains its antihypertensive effect during concomitant therapy with non-steroidal anti-inflammatory drugs (NSAID). Felodipine has anti-anginal and anti-ischaemic effects due to improved myocardial oxygen supply/demand balance. Coronary vascular resistance is decreased and coronary blood flow and myocardial oxygen supply are increased by felodipine due to dilatation of both epicardial arteries and arterioles. Felodipine effectively counteracts coronary vasospasm.
    [Show full text]
  • Mefenamic Acid)
    Ponstan/LPD/PK-04 PONSTAN® (Mefenamic Acid) 1. NAME OF THE MEDICINAL PRODUCT PONSTAN®, PONSTAN® FORTE, PONSTAN® FLASH, PONSTAN® SUSPENSION 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active Ingredient: Mefenamic acid Mefenamic acid is available as: PONSTAN® Suspension: containing 50 mg/5 mL mefenamic acid PONSTAN® Tablets: containing 250 mg mefenamic acid PONSTAN® Forte Tablets: containing 500 mg mefenamic acid PONSTAN® Flash Tablet: containing 250 mg mefenamic acid 3. PHARMACEUTICAL FORM Suspension, Tablet 4. CLINICAL PARTICULARS 4.1. THERAPEUTIC INDICATIONS PONSTAN® is indicated for: 1) The symptomatic relief of rheumatoid arthritis (including Still's Disease), osteoarthritis,6,7,8,9,10,11 and pain including muscular, traumatic and dental pain, headaches of most aetiology, post-operative and postpartum pain12,13,14 2) The symptomatic relief of primary dysmenorrhoea15 3) Menorrhagia due to dysfunctional causes or the presence of an intrauterine device (IUD) when organic pelvic pathology has been excluded16,17,18 4) Premenstrual syndrome19,20,21 5) The relief of pyrexia in paediatric patients over 6 months of age22,23,24 4.2. POSOLOGY AND METHOD OF ADMINISTRATION30 Undesirable effects may be minimized by using the minimum effective dose for the shortest duration necessary to control symptoms.36 The oral dosage form of mefenamic acid may be taken with food if gastrointestinal upset occurs. Mild to moderate pain/rheumatoid arthritis/osteoarthritis in adults and adolescents over 14 years of age: 500 mg three times daily. 1 According to CDS Version 14 Dated 01 November 2019; Supersedes CDS Version 13 Dated: 15 August 2018 Ponstan/LPD/PK-04 Dysmenorrhoea: 500 mg three times daily, to be administered at the onset of menstrual pain and continued while symptoms persist according to the judgement of the physician.
    [Show full text]
  • Accurate Measurement, and Validation of Solubility Data † ‡ ‡ § † ‡ Víctor R
    Article Cite This: Cryst. Growth Des. 2019, 19, 4101−4108 pubs.acs.org/crystal In the Context of Polymorphism: Accurate Measurement, and Validation of Solubility Data † ‡ ‡ § † ‡ Víctor R. Vazqueź Marrero, , Carmen Piñero Berríos, , Luz De Dios Rodríguez, , ‡ ∥ ‡ § Torsten Stelzer,*, , and Vilmalí Lopez-Mej́ ías*, , † Department of Biology, University of Puerto RicoRío Piedras Campus, San Juan, Puerto Rico 00931, United States ‡ Crystallization Design Institute, Molecular Sciences Research Center, University of Puerto Rico, San Juan, Puerto Rico 00926, United States § Department of Chemistry, University of Puerto RicoRío Piedras Campus, San Juan, Puerto Rico 00931, United States ∥ Department of Pharmaceutical Sciences, University of Puerto RicoMedical Sciences Campus, San Juan, Puerto Rico 00936, United States *S Supporting Information ABSTRACT: Solubility measurements for polymorphic com- pounds are often accompanied by solvent-mediated phase transformations. In this study, solubility measurements from undersaturated solutions are employed to investigate the solubility of the two most stable polymorphs of flufenamic acid (FFA forms I and III), tolfenamic acid (TA forms I and II), and the only known form of niflumic acid (NA). The solubility was measured from 278.15 to 333.15 K in four alcohols of a homologous series (methanol, ethanol, 1- propanol, n-butanol) using the polythermal method. It was established that the solubility of these compounds increases with increasing temperature. The solubility curves of FFA forms I and III intersect at ∼315.15 K (42 °C) in all four solvents, which represents the transition temperature of the enantiotropic pair. In the case of TA, the solubility of form II could not be reliably obtained in any of the solvents because of the fast solvent- mediated phase transformation.
    [Show full text]
  • Sharon R. Roseman, MD, FACP Practice Limited to Gastroenterology
    Sharon R. Roseman, MD, FACP Practice Limited to Gastroenterology 701 Broad Street, Suite 411 Sewickley, PA 15143 (412) 749-7160 Fax: (412) 749-7388 http://www.heritagevalley.org/sharonrosemanmd Patient Drug Education for Diltiazem / Nifedipine Ointment Diltiazem/Nifedipine ointment is used to help heal anal fissures. The ointment relaxes the smooth muscle around the anus and promotes blood flow which helps heal the fissure (tear). The ointment reduces anal canal pressure, which diminishes pain and spasm. We use a diluted concentration of Diltiazem/Nifedipine compared to what is typically used for heart patients, and this is why you need to obtain the medication from a pharmacy which will compound your prescription. It is also prescribed to treat anal sphincter spasm, painful hemorrhoids and pelvic floor spasm. The Diltiazem/Nifedipine ointment should be applied 3 times per day, or as directed. A pea-sized drop should be placed on the tip of your finger and then gently placed inside the anus. The finger should be inserted 1/3 – 1/2 its length and may be covered with a plastic glove or finger cot. You may use Vaseline ® to help coat the finger or dilute the ointment. (If you are unable or hesitant to use your finger to administer the ointment TELL U S and we will order you a suppository to use as an “applicator”.) If you are advised to mix the Diltiazem/Nifedipine with steroid ointment, limit the steroids to one to two weeks. The first few applications should be taken lying down, as mild light- headedness or a brief headache may occur.
    [Show full text]
  • Valproate-Olanzapine-Nifedipine Interaction Related Pedal Edema
    Letter-to-the Editor Taiwanese Journal of Psychiatry (Taipei) Vol. 28 No. 3 2014 • 181 • Valproate-olanzapine-nifedipine Interaction Related Pedal Edema Patient’s bilateral pedal pitting edema did not Case Report resolve spontaneously after discontinuing olan- zapine until he received diuretics with furosemide A 45-year-old single male patient with bipo- 40 mg/day and spironolactone 75 mg/day on the lar I disorder was admitted to acute ward of our 21st day of pitting edema. He required further hospital due to depressive mood with irritability treatment, and had normal fi ndings in physical ex- for more than one month. The fi nding of physical amination and repeated laboratory tests. examination at admission revealed no bilateral pedal edema under long-term usage of valproate Comment 700 mg/day as mood stabilizer, nifedipine 30 mg/ day for essential hypertension, and allopurinol There have been some clinical reports to as- 100 mg/day for gouty arthritis before hospitaliza- sociate olanzapine treatment with bilateral lower tion. The results of laboratory tests for electro- extremity edema since 2000 [1]. Pre-clinical trials lytes, renal function, liver function, chest X-ray, of oral olanzapine (doses being equal or greater and electrocardiography were also within normal than 2.5 mg/day) have also reported peripheral limits. edema as a rare adverse event. The pathophysio- During this hospitalization, we added olan- logical mechanism of low extremity edema re- zapine 5 mg/day to control manic symptoms. Five mains unknown, although some mechanisms days later, he reported bilateral swelling over low- could be proposed, such as olanzapine’s blockage er legs and ankles, a bilateral 2+ pitting edema in of α1, M1, M3 and 5-HT2 receptors [2, 3].
    [Show full text]
  • Nifedipine Adalat, Adalat PA, Adalat XL, Apo-Nifed, Nu-Nifed
    Nifedipine Adalat, Adalat PA, Adalat XL, Apo-Nifed, Nu-Nifed Information for patients and families Why am I taking this drug? Nifedipine helps to: Control high blood pressure (hypertension) Reduce how often you have chest pains (angina) How does nifedipine work? Nifedipine belongs to a class of drugs called calcium channel blockers. It relaxes the muscles in your blood vessels so that they will open wider. This lowers your blood pressure and makes it easier for your heart to pump blood. Nifedipine also opens the blood vessels in your heart (coronary arteries) wider so that more blood and oxygen can get to the heart muscle. This is helpful for angina, which happens when the heart muscle is not getting enough blood and oxygen for the amount of work it is doing. How should I take this medicine? Never chew or crush nifedipine tablets. It is best to take nifedipine on an empty stomach. Avoid taking it with grapefruit juice. Take your pills at the same time every day. Do not stop taking this drug unless you check with your doctor first. You may need to gradually take less and less instead of stopping all at once. What should I do if I miss a dose? If you are late taking a dose and it is almost time for the next one, skip the late dose then follow your regular schedule. Never take more than 1 dose at a time. If you do not know what to do, ask your pharmacist, doctor or nurse practitioner. What should I expect from this medicine? Nifedipine usually starts to work within 30 to 60 minutes after you take it.
    [Show full text]